以本所自建的肾癌细胞株（ＧＲＣ１）作为免疫原，用亮氨酸甲基酯（ＬｅｕＯＭｅ）处理免疫后的脾细胞，可以显著提高细胞融合率，并且筛选到４株抗人肾癌单克隆抗体（ＭＡｂ）。ＹＤ５为其中特异性较好的１株，属ＩｇＧ１亚类，在正常肾组织的肾小管、大多数肾癌（１３／１５）组织中表达，且与其它被检正常组织交叉反应少。当以某些肿瘤细胞株作为免疫原且融合率很低时，用ＬｅｕＯＭｅ处理法来提高融合率是很有意义的 The self-built renal cell carcinoma cell line (GRC-1) as an immunogen, leucine methyl ester (LeuOMe) treatment of immune spleen cells, can significantly improve the rate of cell fusion and screening of four anti-human RCC monoclonal antibody (MAb). YD  5 is one of them with better specificity. It belongs to the IgG1 subclass and is expressed in the renal tubules of most normal renal tissues and mostly in renal cell carcinoma (13/15) tissues, and has less cross-reactivity with other normal tissues tested. When using certain tumor cell lines as immunogens with low fusion rates, it is interesting to increase the fusion rate with LeuOMe treatment